Request a demo specialized to your need.
A biotech running its first trial can usually manage the budget with a spreadsheet and one person who knows where everything stands. That setup works fine right up until the second study starts, then a third, and suddenly the same person is tracking multiple site networks, multiple currencies in some cases, and multiple sets of milestone payments, still using the same tools that were only ever built for one study at a time. The pain isn't that budget management got harder in the abstract. It's that the process never actually changed to match the new scale.
Here are six specific reasons this transition is harder than it looks, and why it tends to hit growing biotechs particularly hard.
1. Budget knowledge concentrates in one person by default
At small scale, it's efficient for one person to hold the full picture in their head, supplemented by a spreadsheet. As study count grows, that same setup becomes a single point of failure if that person is unavailable, on leave, or moves on, the institutional knowledge of how each study's budget actually works goes with them.
2. Spreadsheets don't fail cleanly they fail quietly
A spreadsheet built for one study's budget doesn't crash when a second study gets added. It just gets copied, adapted, and gradually diverges from the original in small ways different formulas, different formatting, different assumptions about currency or timing. The failure isn't dramatic; it's a slow accumulation of inconsistency that's hard to notice until numbers across studies stop reconciling.
3. There's rarely a dedicated clinical finance function yet
Larger sponsors have finance teams specifically focused on trial budgets, payments, and reconciliation. A growing biotech often doesn't have that function built out yet — clinical operations, finance, and sometimes the CEO are all touching the same budget process without a clear owner for the trial-specific financial detail.
4. Milestone payment approval becomes a bottleneck
When one person manages all vendor and site payments across a growing portfolio, every approval routes through them, regardless of study or urgency. What was a quick task at one study becomes a queue at three or four, and payment delays start to affect site relationships at exactly the point where site relationships matter most for enrollment.
5. Cash forecasting gets harder exactly when it matters more
A single study's cash needs are relatively predictable. A growing portfolio, with studies at different stages and different payment schedules, creates cash flow patterns that are much harder to forecast manually — right at the moment when accurate forecasting becomes critical for board reporting and fundraising conversations.
6. Investor and board reporting exposes the gaps
Growing biotechs face increasing pressure to report clean, defensible trial spend data to boards and investors. A budget process that was never designed to produce that kind of consolidated, auditable reporting suddenly has to — and stitching it together manually from multiple spreadsheets under a reporting deadline is where a lot of avoidable stress gets created.
What breaks first as a biotech scales
| Pain Point | At One Study | At Three or More Studies |
|---|---|---|
| Budget knowledge | Held by one person, manageable | Single point of failure |
| Tracking method | One spreadsheet, works fine | Multiple diverging spreadsheets |
| Finance ownership | Informal, absorbed by ops | Needs a clearer, dedicated process |
| Payment approvals | Quick, low volume | Bottlenecked through one person |
| Cash forecasting | Straightforward | Complex, harder to predict manually |
| Board/investor reporting | Simple to produce | Requires manual consolidation under deadline |
Why this matters under ICH E6(R3)
Sponsor oversight responsibilities under ICH E6(R3) apply regardless of company size or study count. A growing biotech still needs to demonstrate financial oversight and a defensible audit trail, even while the internal process for managing that oversight is still maturing. Scaling budget management isn't just an efficiency question — it's also about maintaining the kind of oversight evidence that sponsor responsibilities require as complexity increases.
How Cloudbyz CTFM approaches this
Cloudbyz Clinical Trial Financial Management (CTFM) is built to give a growing biotech a structured budget process from the start, rather than requiring a rebuild once spreadsheets stop scaling. Budgets, invoices, and payment status live in one system rather than being reconstructed from separate files, and the Financial Navigator can answer plain-English questions about payment and budget status without requiring a single person to hold that information from memory. Because the Invoice Reconciliation Agent flags aging invoices and exceptions automatically, payment approvals don't have to bottleneck through one overloaded reviewer as study count grows.
What this means by role
- Founders and Clinical Operations leads at growing biotechs get a budget process that doesn't depend entirely on one person's institutional knowledge.
- Study Finance Leads get consolidated, auditable reporting that doesn't require manually reconciling spreadsheets under a board deadline.
- Clinical Operations Directors managing an expanding study portfolio get payment approval workflows that scale with study count instead of creating a bottleneck.
The transition from one study to a portfolio isn't just "more of the same work." It's a structural shift that most spreadsheet-based processes were never built to absorb and catching that early is considerably less painful than discovering it during a board reporting cycle.
Book a demo with Cloudbyz.
Subscribe to our Newsletter
